J&J to acquire remainder of Crucell

NEW BRUNSWICK, N.J. Johnson & Johnson is set to buy up the remaining portion of Dutch biotech company Crucell that it doesn’t already own, J&J said Friday.


The drug maker said the two companies were in “advanced negotiations” for J&J to buy up the remainder of Crucell for around $2.3 billion. J&J currently owns slightly less than 18% of the company through an affiliate.



J&J said it would benefit from Crucell’s expertise in vaccines and gain a “strong platform” in the vaccine market. The drug maker said it plans to keep Crucell as the center for vaccines in the conglomerate and maintain its headquarters in Leiden, Netherlands.


Login or Register to post a comment.